Microbiome Biotech Enterome and Takeda sign Crohn's Deal Worth Up To $600 Million+

Microbiome Biotech Enterome and Takeda sign Crohn's Deal Worth Up To $600 Million+

Source: 
CP Wire
snippet: 

ENTEROME SA, on 10/23/18 announced it has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical Company Limited (“Takeda”). The agreement covers Enterome’s lead investigational drug candidate EB8018 in patients with Crohn’s disease, with the potential to expand to other gastrointestinal (GI) disorders and liver diseases.